Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 1c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.64), $0.01 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $2.59 million versus the consensus estimate of $3.94 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight